Christopher Chen
Stock Analyst at Robert W. Baird
(3.22)
# 2,488
Out of 5,023 analysts
6
Total ratings
100%
Success rate
32.4%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Christopher Chen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DFTX Definium Therapeutics | Reiterated: Buy | $57 → $79 | $37.40 | +111.23% | 3 | Sep 15, 2026 | |
| AMLX Amylyx Pharmaceuticals | Reiterated: Buy | $28 → $52 | $27.79 | +87.12% | 2 | Aug 18, 2026 | |
| LRMR Larimar Therapeutics | Reiterated: Buy | $5 | $2.96 | +68.92% | 1 | Jun 30, 2026 |
Definium Therapeutics
Sep 15, 2026
Reiterated: Buy
Price Target: $57 → $79
Current: $37.40
Upside: +111.23%
Amylyx Pharmaceuticals
Aug 18, 2026
Reiterated: Buy
Price Target: $28 → $52
Current: $27.79
Upside: +87.12%
Larimar Therapeutics
Jun 30, 2026
Reiterated: Buy
Price Target: $5
Current: $2.96
Upside: +68.92%